Search clinical trials for: SEP-363856 75 mg

Total 287 results

Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Schizophrenia

Japan, Taiwan, China, Philippines
Sumitomo Pharma America, Inc.

Completed

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Schizophrenia

United States, Serbia, Colombia, Bulgaria, Russian Federation, Ukraine
Sumitomo Pharma America, Inc.

Completed

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Schizophrenia

United States, Serbia, Croatia, Bulgaria, Latvia, Russian Federation, Ukraine
Sunovion

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (SEP-363856)

Schizophrenia

United States
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Schizophrenia

Japan
Sumitomo Pharma America, Inc.

Terminated

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

Schizophrenia

United States, Serbia, Ukraine, Croatia, Colombia, Russian Federation, Bulgaria, Latvia
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

Schizophrenia

Japan
Sunovion

Completed

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

Schizophrenia

United States, Ukraine, Russian Federation, Hungary, Romania
Sumitomo Pharma America, Inc.

Completed

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Schizophrenia

Japan
Sunovion

Completed

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Recruiting

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States, Spain, Japan, Bulgaria, Estonia, Finland, Slovakia, Sweden
Sunovion

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis

United States
Sunovion

Completed

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

Schizophrenia

Hungary, United States, Romania, Ukraine, Russian Federation
Otsuka Pharmaceutical Development & Commercialization...
Sumitomo Pharma Co., Ltd.; Sumitomo Pharma America, Inc.

Recruiting

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Sumitomo Pharma America, Inc.

Completed

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Enrolling by invitation

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Completed

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

Schizophrenia

United States
Sunovion

Completed

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

Schizophrenia

United Kingdom
Sunovion

Completed

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

Schizophrenia

United States
Sunovion

Completed

A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

Depressive Episode | Bipolar 1 Depression

Japan, Serbia, United States, Poland, Russian Federation, Bulgaria, Slovakia, Ukraine
Massachusetts General Hospital

Completed

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Attention Deficit Hyperactivity Disorder

United States
Sumitomo Pharma America, Inc.

Terminated

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Depressive Episodes, Bipolar I Depression

United States, Bulgaria, Japan, Romania, Canada, Slovakia
Ruijin-Hainan Hospital Shanghai Jiao Tong University...

Recruiting

A Prospective Real World Study of Rimegepant in the Treatment of Migraine

Migraine

China
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)

Non Small Cell Lung Cancer | BRAF V600E

France
EMD Serono

Terminated

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

Lupus Erythematosus, Systemic

United States, Korea, Republic of, Bulgaria, Argentina, Mexico, Italy, Spain, Philippines, Germany, Czechia, Chile, Poland, Peru, United Kingdom, South Africa, Brazil, Russian Federation
University of Florence
Azienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaborators

Recruiting

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment (RAISE)

Migraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura

Italy
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Multiple Sclerosis Extension Study, Phase II (ATAMS ext)

Relapsing Multiple Sclerosis

Sweden, United States, Czech Republic, Russian Federation, Spain, United Kingdom, Lithuania, Ukraine, Netherlands, Canada, Germany, France, Switzerland, Australia, Belgium, Lebanon, New Caledonia
Mayo Clinic
Pfizer

Not yet recruiting

Comparison of Rimegepant and Placebo for Pain in IBS

Irritable Bowel Syndrome

United States
Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
Arthrosi Therapeutics

Recruiting

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients

Hyperuricemia | Gout | Arthritis, Gouty | Gout Chronic

United States, Australia, New Zealand
GlaxoSmithKline

Completed

Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance

Gastroparesis

Australia
Pfizer

Completed

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Migraine

Japan
Hepion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3 (ALTITUDE)

NASH With Fibrosis

United States
EMD Serono

Completed

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus (ADDRESS II)

Lupus Erythematosus, Systemic

Korea, Republic of, Philippines, Spain, United States, Czechia, Germany, United Kingdom, South Africa, Poland, Argentina, Italy, Chile, Bulgaria, Japan, Brazil, Mexico, Peru, Russian Federation
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) (APRIL-SLE)

Lupus Erythematosus, Systemic

United States, Croatia, Bulgaria, France, Korea, Republic of, Poland, Russian Federation, South Africa, Spain, United Kingdom, Germany, Malaysia, Latvia, Lithuania, Ukraine, Argentina, Israel, Netherlands, Greece, Taiwan, Philip... and more
PHARMENTERPRISES LLC

Not yet recruiting

Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis

Cystitis

Russian Federation
Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Completed

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

United States
Novartis Pharmaceuticals

Completed

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)

Anklyosing Spondylitis

Germany, Austria, Spain, Switzerland, United Kingdom, United States, Singapore, Russian Federation, Netherlands, Italy, Finland, Czechia, Canada
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Efficacy and Safety of Atacicept in IgA Nephropathy

IgA Nephropathy

United States, Japan, United Kingdom
Cinclus Pharma Holding AB

Active, not recruiting

Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects

GERD

Slovenia
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, Germany
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Hypertension

United States, Belgium, Hungary, Turkey, Guatemala, Slovakia, Germany, Puerto Rico, Poland
Novartis Pharmaceuticals

Withdrawn

A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture

Asthma
ObsEva SA

Terminated

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

Endometriosis

United States, Canada, Puerto Rico
Kissei Pharmaceutical Co., Ltd.

Completed

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

Endometriosis

United States, Austria, Bulgaria, Czechia, France, Poland, Romania, Spain, Ukraine
Kissei Pharmaceutical Co., Ltd.

Terminated

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 5)

Endometriosis

United States, Canada, Puerto Rico
AstraZeneca

Completed

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. (SELECT-2)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria
University of Florence
Azienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaborators

Recruiting

Gepant treAtments: EffectIveNess and tolERability (GAINER) (GAINER)

Migraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura

Italy
Austarpharma, LLC

Unknown

Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers

Bioequivalence

United States

Search clinical trials for: SEP-363856 75 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations